Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia
Brief Summary: This randomized phase III trial is studying fludarabine, cyclophosphamide, and rituximab to see how well they work compared to fludarabine and cyclophosphamide in treating patients with B-cell chronic lymphocytic leukemia.


Options:
A: Arm Label: Fludarabine+Cyclophosphamide+Rituximab (FCR); Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: Cyclophosphamide, Drug: Fludarabine Phosphate | Arm Label: Fludarabine+Cyclophosphamide (FC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Fludarabine Phosphate | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Fludarabine+Cyclophosphamide+Rituximab (FCR) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Fludarabine+Cyclophosphamide (FC), Fludarabine+Cyclophosphamide+Rituximab (FCR) | Intervention Type: DRUG; Name: Fludarabine Phosphate; Assigned to Arm(s): Fludarabine+Cyclophosphamide (FC), Fludarabine+Cyclophosphamide+Rituximab (FCR)
B: Arm Label: Arm A - Obinutuzumab in Combination with Chlorambucil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Obinutuzumab, Drug: Chlorambucil | Arm Label: Arm B - Acalabrutinib in Combination with Obinutuzumab; Type: EXPERIMENTAL; Interventions: Drug: Acalabrutinib, Drug: Obinutuzumab | Arm Label: Arm C - Acalabrutinib Monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Acalabrutinib | Intervention Type: DRUG; Name: Acalabrutinib; Assigned to Arm(s): Arm B - Acalabrutinib in Combination with Obinutuzumab, Arm C - Acalabrutinib Monotherapy | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): Arm A - Obinutuzumab in Combination with Chlorambucil, Arm B - Acalabrutinib in Combination with Obinutuzumab | Intervention Type: DRUG; Name: Chlorambucil; Assigned to Arm(s): Arm A - Obinutuzumab in Combination with Chlorambucil
C: Arm Label: Cohort 1: Bendamustine + Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: Rituximab | Arm Label: Cohort 1: Zanubrutinib; Type: EXPERIMENTAL; Interventions: Drug: Zanubrutinib | Arm Label: Cohort 1a (China only): Bendamustine + Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: Rituximab | Arm Label: Cohort 1a (China only): Zanubrutinib; Type: EXPERIMENTAL; Interventions: Drug: Zanubrutinib | Arm Label: Cohort 2: Zanubrutinib; Type: EXPERIMENTAL; Interventions: Drug: Zanubrutinib | Arm Label: Cohort 3: Venetoclax + Zanubrutinib; Type: EXPERIMENTAL; Interventions: Drug: Zanubrutinib, Drug: Venetoclax | Intervention Type: DRUG; Name: Zanubrutinib; Assigned to Arm(s): Cohort 1: Zanubrutinib, Cohort 1a (China only): Zanubrutinib, Cohort 2: Zanubrutinib, Cohort 3: Venetoclax + Zanubrutinib | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Cohort 1: Bendamustine + Rituximab, Cohort 1a (China only): Bendamustine + Rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Cohort 1: Bendamustine + Rituximab, Cohort 1a (China only): Bendamustine + Rituximab | Intervention Type: DRUG; Name: Venetoclax; Assigned to Arm(s): Cohort 3: Venetoclax + Zanubrutinib
D: Arm Label: Arm A (ibrutinib, rituximab); Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib, Other: Laboratory Biomarker Analysis, Other: Pharmacogenomic Study, Other: Quality-of-Life Assessment, Biological: Rituximab | Arm Label: Arm B (rituximab, fludarabine phosphate, cyclophosphamide); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Fludarabine Phosphate, Other: Laboratory Biomarker Analysis, Other: Pharmacogenomic Study, Other: Quality-of-Life Assessment, Biological: Rituximab | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: DRUG; Name: Fludarabine Phosphate; Assigned to Arm(s): Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Arm A (ibrutinib, rituximab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: OTHER; Name: Pharmacogenomic Study; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide)

Answer: A